PD-0809 4-year PSA to predict relapse risk after low dose rate brachytherapy for prostate cancer. (August 2021) - Noble, D.; Doyle, E.; Tramonti, G.; Law, A.; Sundaramurthy, A.; Brush, J.; Keanie, J.; Wood, C.; Drewell, P.; Keough, W.; McLaren, D.